UK clinical trial regulations are the regulatory framework that apply specifically to clinical trials of investigational medicinal products (CTIMPs) conducted in the UK: studies designed to generate evidence on the efficacy or safety of medicines.
Important key facts
The Medicines and Healthcare Products Regulatory Agency (MHRA) holds authority over clinical trial approvals, oversight, and inspections across England, Wales, Scotland, and Northern Ireland.
The Combined Review process sits at the heart of UK clinical trial approval. A single application through the Integrated Research Application System (IRAS) goes simultaneously to both the MHRA and a Research Ethics Committee (REC).
Trial registration is a condition of REC approval, not an optional step. Trials submitted on or after 1 January 2022 receive automatic registration with the ISRCTN Registry through the HRA, unless an alternative is arranged.
In the UK, there is one key obligations for the sponsor role:
- If an organization isn’t established in the UK or an approved country, a UK-based legal representative must be appointed
Importantly, the updated UK clinical trial regulation from 2026 mark a genuine turning point for sponsors.
For commercial sponsors contracting with the National Health Service (NHS) and health and social care organizations, the April 2026 versions of “Model Clinical Trial Agreements” are mandatory. These updated agreements reflect the amended regulations and bring in new terminology. Existing agreements stay in place – but any new contract signed on or after 28 April 2026 must use the current version.
A faster approval process, clearer modification categories, simplified safety reporting, and updated archiving requirements – each element of the updated UK clinical trial regulation reshapes how clinical programs are now planned and run under the UK clinical trials regulations.